United States Military Hospitals Adopt HemaClear Tourniquet
Joint Task Force National Capital Region Medical (JTF CapMed) in Bethesda, Md., has adopted the HemaClear single-use, sterile tourniquet device for bloodless orthopedic procedures. JTF CapMed treats wounded, ill and injured, active duty, and retired service members and their families.
As a result, the Walter Reed National Military Medical Center and Fort Belvoir Community Hospital in Bethesda will begin using the HemaClear tourniquet device, and will have it readily available to treat military orthopedic patients. This is a significant milestone for HemaClear, as the company has been focusing on the goal of expanding the tourniquet device’s use in Military Army Surgical Hospital (commonly known as MASH) units within battle zones. The company asserts that military physicians can guarantee the device’s sterility without relying on an electronic box for a reliable occlusion.
“It is humbling to see that veterans are receiving top-notch care from physicians,” said Grant Castor, national sales manager of OHK Medical Devices, the company that manufactures HemaClear’s device. “HemaClear enables physicians to perform procedures bloodless more proximally, thus reducing the amount of blood loss, increasing the visibility for the physician, and contributing to a better outcome for the patient.”
Bloodless procedures have the advantage of reducing infection rates and increasing the surgical field. Bloodless surgical technology makes surgery easier to perform, cheaper to administer, and altogether safer for patients.
Founded in 1999 by an international team of medical specialists and engineers, HemaClear is a privately held company based in Haifa, Israel. OHK Medical is located in the same city, and is concerned with the development and manufacture of self-contained, sterile, and exsanguinating tourniquets for hospitals.